Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
| Status: | Completed |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | 50 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | July 2010 |
| End Date: | December 2010 |
A Phase 2 Clinical Trial Evaluating the Incidence of Upper Gastrointestinal Mucosal Damage Following Administration of Either PL3100 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated GI Damage
The purpose of this study is to determine the subchronic gastrointestinal (GI) safety of
PL3100 versus Naproxen in normal healthy volunteers.
PL3100 versus Naproxen in normal healthy volunteers.
Inclusion Criteria (Selected)
- Male and female healthy adult subjects
Exclusion Criteria (Selected)
- Subject has protocol specified significant medical history.
- Subject is currently participating, or has participated within 30 days prior to study
entry, in an investigational drug study.
- Subject has hypersensitivity or contraindications to naproxen, ibuprofen, or other
NSAID.
We found this trial at
2
sites
Dallas VA Medical Center VA North Texas Health Care System (VANTHCS) is a progressive health...
Click here to add this to my saved trials
Click here to add this to my saved trials